Ticker Details
Ardelyx, Inc. Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases.
IPO Date:	June 19, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.5B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 3.19%
Avg Daily Range (30 D):	$0.12 | 2.03%
Avg Daily Range (90 D):	$0.15 | 2.42%

Institutional Daily Volume
Avg Daily Volume:	2.49M
Avg Daily Volume (30 D):	2.7M
Avg Daily Volume (90 D):	3.59M

Trade Size
Avg Trade Size (Sh.):	259
Avg Trade Size (Sh.) (30 D):	141
Avg Trade Size (Sh.) (90 D):	157

Institutional Trades
Total Institutional Trades:	1,699
Avg Institutional Trade:	$2.18M
Avg Institutional Trade (30 D):	$1.98M
Avg Institutional Trade (90 D):	$2.02M
Avg Institutional Trade Volume:	.42M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.89M
Avg Closing Trade (30 D):	$2.84M
Avg Closing Trade (90 D):	$2.88M
Avg Closing Volume:	534.76K

News

Apr 3, 2026 @ 3:11 PM Ardelyx President and CEO Sells 41,000 Shares for ... Source: Sarah Sidlow

Apr 1, 2026 @ 12:01 PM Rajani Dinavahi, MD, Appointed Chief Medical Offic... Source: Na

Feb 5, 2026 @ 1:00 PM Ardelyx to Report Full Year and Fourth Quarter 202... Source: Na

Jan 23, 2026 @ 5:56 PM Breaking Barriers: How 2026’s Top Clinical ... Source: Equity Insider

Jun 2, 2025 @ 5:50 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.26	$-.01	$-.26
Diluted EPS	$-.26	$-.01	$-.26
Revenue	$407.32M	$125.22M	$407.32M
Gross Profit	$367.78M	$114.37M	$367.78M
Net Income / Loss	$-61.6M	$-.41M	$-61.6M
Operating Income / Loss	$-40.98M	$5.1M	$-40.98M
Cost of Revenue	$39.54M	$10.85M	$39.54M
Net Cash Flow	$3.07M	$25.28M	$3.07M
PE Ratio